Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 21233243)

1.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

2.

Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.

Zhang X, Lancet JE, Zhang L.

Leuk Lymphoma. 2015 May 26:1-9. [Epub ahead of print]

PMID:
25927244
3.

Current and novel therapeutic approaches in myelodysplastic syndromes.

Estephan F, Tiu RV.

J Community Support Oncol. 2014 Jul;12(7):236-249. doi: 10.12788/jcso.0057. Review.

PMID:
25830232
4.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

PMID:
25736003
5.

Established and novel agents for myelodysplastic syndromes.

Sekeres MA, Gerds AT.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):82-9. doi: 10.1182/asheducation-2014.1.82. Epub 2014 Nov 18.

PMID:
25696839
6.

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM.

J Blood Med. 2014 Dec 22;6:1-16. doi: 10.2147/JBM.S50482. eCollection 2015. Review.

7.

A primary care approach to myelodysplastic syndromes.

Samiev D, Bhatt VR, Armitage JD, Maness LJ, Akhtari M.

Korean J Fam Med. 2014 May;35(3):111-8. doi: 10.4082/kjfm.2014.35.3.111. Epub 2014 May 22. Review.

8.

Molecular pathogenesis of myelodysplastic syndromes.

Visconte V, Selleri C, Maciejewski JP, Tiu RV.

Transl Med UniSa. 2014 Feb 4;8:19-30. eCollection 2014 Jan.

9.

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes.

Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA.

Cancer. 2014 Jun 1;120(11):1670-6. doi: 10.1002/cncr.28631. Epub 2014 Feb 27.

10.

[Myelodysplastic syndromes --  therapy progress over the last two decades].

Jonášová A.

Vnitr Lek. 2013 Jul;59(7):635-40. Czech.

PMID:
23909274
11.

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.

Bejar R, Tiu RV, Sekeres MA, Komrokji RS.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e256.

12.

How we treat lower-risk myelodysplastic syndromes.

Fenaux P, Adès L.

Blood. 2013 May 23;121(21):4280-6. doi: 10.1182/blood-2013-02-453068. Epub 2013 Apr 10. Review.

13.

[Present and future prospects of MDS therapy].

Nakamura Y, Mitani K.

Rinsho Ketsueki. 2013 Jan;54(1):29-36. Review. Japanese. No abstract available.

PMID:
23391644
14.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q).

Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.

15.

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.

Leitch HA, Buckstein R, Shamy A, Storring JM.

Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92. doi: 10.1016/j.critrevonc.2012.07.003. Epub 2012 Aug 15. Review.

PMID:
22901762
16.

Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction.

Smith BD.

Am J Med. 2012 Jul;125(7 Suppl):S26-30. doi: 10.1016/j.amjmed.2012.04.020.

17.

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, Petrucci L, Salaroli A, Serrao A, Latagliata R, Alimena G.

Ann Hematol. 2012 Sep;91(9):1345-9. doi: 10.1007/s00277-012-1481-7. Epub 2012 May 9.

PMID:
22569854
18.

Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa.

Louw VJ, Bassa F, Chan SW, Dreosti L, Du Toit M, Ferreira M, Gartrell K, Gunther K, Jogessar V, Littleton N, Mahlangu J, McDonald A, Patel M, Pool R, Ruff P, Schmidt A, Sissolak G, Swart A, Verburgh E, Webb MJ.

S Afr Med J. 2011 Nov 28;101(12):900-6.

PMID:
22273034
19.

Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K.

Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.

PMID:
22172461
20.

MDS: Refining existing therapy through improved biologic insights.

Schecter J, Galili N, Raza A.

Blood Rev. 2012 Mar;26(2):73-80. doi: 10.1016/j.blre.2011.11.001. Epub 2011 Dec 1. Review.

PMID:
22137600
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk